
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics is projected to see a 50% upside in a positive outcome on October 3rd, which aligns with their 90% powered HOPE-3 trial 1.1 point difference, revealing a 1.2 point difference in decline for the PUL 2.0 at 12 months. Additionally, the Lancet publication reports significantly improved LVEF results, especially in patients with baseline cardiomyopathy, which supports Capricor's BLA amendment and request for a refined indication. Based on this information, the company's high revenue potential and potential for approval and partnership makes it a strong buy with a target price of $25.
Bears say
Capricor Therapeutics is facing significant regulatory risks with uncertainties in the approval pathway for Deramiocel, its allogenic cell therapy. The recent AdCom and lack of clarity on the sufficiency of data for a regulatory filing raise concerns about the viability of Deramiocel's approval. The company's upcoming WMS presentation of HOPE-3 data, if positive, could potentially redirect the narrative towards the upper-limb indication. However, the need for unprecedented agency action and the company's current financials indicate a negative outlook.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares